Search results
Results from the WOW.Com Content Network
The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]
As they are administered by injection (intravenous, intramuscular or subcutaneous), they are less suitable for long-term treatment. [ 1 ] Argatroban (as well as the hirudins) is used for heparin-induced thrombocytopenia , a relatively infrequent yet serious complication of heparin treatment that requires anticoagulation (as it increases both ...
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.
HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use RISPERDAL ® safely and effectively. See full prescribing information for
Antiplatelet medications are one of the primary recommendations for treatment of both stable [4] and unstable [5] ischemic heart disease.Most commonly, aspirin is used as a single medication in cases of uncomplicated stable angina, and in some cases of unstable angina.
A loading dose is most useful for drugs that are eliminated from the body relatively slowly, i.e. have a long systemic half-life. Such drugs need only a low maintenance dose in order to keep the amount of the drug in the body at the appropriate therapeutic level, but this also means that, without an initial higher dose, it would take a long ...
The structure of apixaban, before adjusting the moiety's for maximum potency. Apixaban. The 13F moiety intermediate before apixaban was fully developed. During the SAR development of apixaban there were three groups that needed to be tested to attain maximum potency and bioavailability.
to order in one experimental treatment. Thus, the avoidance of small immediate costs – the cost of the extra effort required to order a less healthy meal – weighs in favor of healthy selections. The second bias, well documented in the Behavioral Economics literature, is the tendency